Please assess the completion status of the following clinical trial:

Trial Title: Study of the Efficacy of SBRT on Unresectable Peripheral Primary Tumor

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years ≤ Age ≤ 75 years~* PS ECOG 0 or 1~* Histologically proven NSCLC~* Unresectable stage III: T1 or T2 or T3 ≤ 5 cm AND N2 or N3 (only contralateral mediastinum or homolateral supraclavicular).~* Peripheral primary tumor ≥ 1 cm and ≤ 5 cm~* Possible concomitant chemoradiotherapy : 1 cure induction and 3 concomitant cycles of chemotherapy with cisplatin and Navelbine ® and 3D conformal radiotherapy delivering 66 Gy in 33 fractions to the mediastinal lymph node involvement without treating the peripheral tumor.~* Adequate biological parameters~* Forced expiratory volume (FEV) ≥1 liter or ≥ 30% of the theoretical value~* Patient covered by a health insurance scheme~* Signed informed consent~Exclusion Criteria:~* SCLC or large cell neuroendocrine carcinoma~* Metastatic disease~* Stage IVa~* Pregnant or breast-feeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- SBRT (Type: EXPERIMENTAL): Study treatment = SBRT for peripheral primary tumor.

Based on this trial design, predict the completion outcome and termination type (if applicable).